<p>加拿大温哥華，2025 年 12 月 31 日（GLOBE NEWSWIRE）-- Clearmind Medicine Inc.（納斯達克代碼：CMND），（法蘭克福證券交易所代碼：CWY0）（“Clearmind” 或 “公司”）是一家臨牀階段的生物技術公司，專注於發現和開發新型神經塑性藥物，以解決主要的未得到充分治療的健康問題。公司宣佈已收到納斯達克證券市場（“納斯達克”）上市資格部門的通知信，告知公司已重新符合納斯達克上市規則 5550(a)(2) 中規定的最低出價價格要求。</p>
<p>公司此前已宣佈，2025 年 12 月 4 日收到納斯達克的通知，稱其未符合納斯達克上市規則 5550(a)(2) 中規定的最低出價價格要求，因為公司普通股的收盤出價在連續 30 個交易日內低於 1.00 美元。</p>
<p>2025 年 12 月 30 日，納斯達克向公司確認，在 2025 年 12 月 15 日至 12 月 29 日的最後 10 個連續交易日內，公司普通股的收盤出價為每股 1.00 美元或更高，因此公司已重新符合上市規則 5550(a)(2)，該事項現已結束。</p>
<p><strong>關於 Clearmind Medicine Inc.</strong></p>
<p>Clearmind 是一家臨牀階段的迷幻藥物生物技術公司，專注於發現和開發新型迷幻藥物，以解決廣泛且未得到充分關注的健康問題，包括酒精使用障礙。其主要目標是研究和開發基於迷幻藥的化合物，並嘗試將其商業化為受監管的藥物、食品或補充劑。</p>
<p>公司的知識產權組合目前包括十九個專利系列，涵蓋 31 項已授予專利。公司打算在必要時為其化合物申請更多專利，並將對獲取額外知識產權持開放態度，以擴展其組合。</p>
<p>Clearmind 的股票在納斯達克以 “CMND” 符號交易，在法蘭克福證券交易所以 “CWY0” 符號交易。</p>
<p>欲瞭解更多信息，請訪問：https://www.clearmindmedicine.com 或聯繫：</p>
<p>投資者關係</p>
<p>invest@clearmindmedicine.com</p>
<p>電話：（604）260-1566</p>
<p>美國：CMND@crescendo-ir.com</p>
<p>一般諮詢</p>
<p>Info@Clearmindmedicine.com</p>
<p>www.Clearmindmedicine.com</p>
<p><strong>前瞻性聲明：</strong></p>
<p>本新聞稿包含《私人證券訴訟改革法案》和其他證券法所定義的 “前瞻性聲明”。諸如 “預計”、“預期”、“打算”、“計劃”、“相信”、“尋求”、“估計” 等詞語或類似表達的變體旨在識別前瞻性聲明。例如，當公司討論推進針對 AUD 的創新治療、來自患者和領先臨牀機構對 CMND-100 的高度關注、CMND-100 轉變 AUD 治療的潛力以及其相信這一快速進展使其能夠生成額外有價值的數據，從而更接近提供解決成癮根本原因的突破性療法並改善安全性時，公司正在使用前瞻性聲明。前瞻性聲明不是歷史事實，而是基於管理層當前的期望、信念和預測，這些預測本質上具有不確定性。這些期望、信念和預測是以善意表達的。然而，無法保證管理層的期望、信念和預測將會實現，實際結果可能與前瞻性聲明中所表達或暗示的內容有重大差異。前瞻性聲明受到風險和不確定性的影響，這可能導致實際表現或結果與前瞻性聲明中所表達的內容有重大差異。有關影響公司的風險和不確定性的更詳細描述，請參考公司不時向證券交易委員會（“SEC”）提交的報告，包括但不限於公司截至 2024 年 10 月 31 日的年度報告（表格 20-F）及其後續向 SEC 提交的文件。前瞻性聲明僅在聲明發布之日有效。公司不承擔更新前瞻性聲明以反映實際結果、後續事件或情況、假設變化或影響前瞻性信息的其他因素變化的義務，除非適用的證券法要求。如果公司更新一項或多項前瞻性聲明，不應推斷公司將就此或其他前瞻性聲明進行額外更新。提供的參考和鏈接僅為方便，網站上包含的信息不被納入本新聞稿。Clearmind 對第三方網站的內容不承擔責任。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EVTVNeU0zTXpRd09ERXhJelV3TURBNE5qa3pOQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EVTVNeU0zTXpRd09ERXhJelV3TURBNE5qa3pOQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2ZjODFhNTktZWY0MC00MzQ4LWIzNzQtMGI3M2RkYzU1YTY5LTUwMDA4NjkzNC0yMDI1LTEyLTMxLWVu/tiny/Clearmind-Medicine-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2ZjODFhNTktZWY0MC00MzQ4LWIzNzQtMGI3M2RkYzU1YTY5LTUwMDA4NjkzNC0yMDI1LTEyLTMxLWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

CMND

<p>Clearmind Medicine Inc. 已經重新符合納斯達克的最低股價要求，因為其股價在連續 10 個交易日內收盤價達到或超過 1.00 美元。此前，該公司因股價在超過 30 天內低於 1.00 美元而收到不合規通知。Clearmind 專注於開發源自迷幻藥的治療方法，以應對未得到充分治療的健康問題，包括酒精使用障礙，並持有 31 項已授予的專利組合</p>

<p>Vancouver, Canada, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &#34;Company&#34;), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).</p>
<div class="lb-trans"><p>加拿大温哥華，2025 年 12 月 31 日（GLOBE NEWSWIRE）-- Clearmind Medicine Inc.（納斯達克代碼：CMND），（法蘭克福證券交易所代碼：CWY0）（“Clearmind” 或 “公司”）是一家臨牀階段的生物技術公司，專注於發現和開發新型神經塑性藥物，以解決主要的未得到充分治療的健康問題。公司宣佈已收到納斯達克證券市場（“納斯達克”）上市資格部門的通知信，告知公司已重新符合納斯達克上市規則 5550(a)(2) 中規定的最低出價價格要求。</p>
</div><p>The Company had previously announced that it was notified by Nasdaq on December 4, 2025, that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), as the closing bid price of the Company’s common shares had been below $1.00 for more than 30 consecutive business days.</p>
<div class="lb-trans"><p>公司此前已宣佈，2025 年 12 月 4 日收到納斯達克的通知，稱其未符合納斯達克上市規則 5550(a)(2) 中規定的最低出價價格要求，因為公司普通股的收盤出價在連續 30 個交易日內低於 1.00 美元。</p>
</div><p>On December 30, 2025, Nasdaq provided confirmation to the Company that for the last 10 consecutive business days, from December 15 through December 29, 2025, the closing bid price of the Company’s common shares was $1.00 per share or greater, that the Company has hence regained compliance with Listing Rule 5550(a)(2) and that the matter is now closed.</p>
<div class="lb-trans"><p>2025 年 12 月 30 日，納斯達克向公司確認，在 2025 年 12 月 15 日至 12 月 29 日的最後 10 個連續交易日內，公司普通股的收盤出價為每股 1.00 美元或更高，因此公司已重新符合上市規則 5550(a)(2)，該事項現已結束。</p>
</div><p><strong>About Clearmind Medicine Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 Clearmind Medicine Inc.</strong></p>
</div><p>Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.</p>
<div class="lb-trans"><p>Clearmind 是一家臨牀階段的迷幻藥物生物技術公司，專注於發現和開發新型迷幻藥物，以解決廣泛且未得到充分關注的健康問題，包括酒精使用障礙。其主要目標是研究和開發基於迷幻藥的化合物，並嘗試將其商業化為受監管的藥物、食品或補充劑。</p>
</div><p>The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.</p>
<div class="lb-trans"><p>公司的知識產權組合目前包括十九個專利系列，涵蓋 31 項已授予專利。公司打算在必要時為其化合物申請更多專利，並將對獲取額外知識產權持開放態度，以擴展其組合。</p>
</div><p>Shares of Clearmind are listed for trading on Nasdaq under the symbol &#34;CMND&#34; and the Frankfurt Stock Exchange under the symbol “CWY0.”</p>
<div class="lb-trans"><p>Clearmind 的股票在納斯達克以 “CMND” 符號交易，在法蘭克福證券交易所以 “CWY0” 符號交易。</p>
</div><p>For further information, visit: https://www.clearmindmedicine.com or contact:</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問：https://www.clearmindmedicine.com 或聯繫：</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投資者關係</p>
</div><p>invest@clearmindmedicine.com</p>
<div class="lb-trans"><p>invest@clearmindmedicine.com</p>
</div><p>Telephone: (604) 260-1566</p>
<div class="lb-trans"><p>電話：（604）260-1566</p>
</div><p>US: CMND@crescendo-ir.com</p>
<div class="lb-trans"><p>美國：CMND@crescendo-ir.com</p>
</div><p>General Inquiries</p>
<div class="lb-trans"><p>一般諮詢</p>
</div><p>Info@Clearmindmedicine.com</p>
<div class="lb-trans"><p>Info@Clearmindmedicine.com</p>
</div><p>www.Clearmindmedicine.com</p>
<div class="lb-trans"><p>www.Clearmindmedicine.com</p>
</div><p><strong>Forward-Looking Statements:</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明：</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses advancing innovative treatments for AUD, the high level of interest from both patients and leading clinical sites in CMND-100, CMND-100’s potential to transform AUD treatment and its belief that that this rapid progress positions it to generate additional valuable data, bringing it closer to delivering a breakthrough therapy that addresses the root causes of addiction with an improved safety profile. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.</p>
<div class="lb-trans"><p>本新聞稿包含《私人證券訴訟改革法案》和其他證券法所定義的 “前瞻性聲明”。諸如 “預計”、“預期”、“打算”、“計劃”、“相信”、“尋求”、“估計” 等詞語或類似表達的變體旨在識別前瞻性聲明。例如，當公司討論推進針對 AUD 的創新治療、來自患者和領先臨牀機構對 CMND-100 的高度關注、CMND-100 轉變 AUD 治療的潛力以及其相信這一快速進展使其能夠生成額外有價值的數據，從而更接近提供解決成癮根本原因的突破性療法並改善安全性時，公司正在使用前瞻性聲明。前瞻性聲明不是歷史事實，而是基於管理層當前的期望、信念和預測，這些預測本質上具有不確定性。這些期望、信念和預測是以善意表達的。然而，無法保證管理層的期望、信念和預測將會實現，實際結果可能與前瞻性聲明中所表達或暗示的內容有重大差異。前瞻性聲明受到風險和不確定性的影響，這可能導致實際表現或結果與前瞻性聲明中所表達的內容有重大差異。有關影響公司的風險和不確定性的更詳細描述，請參考公司不時向證券交易委員會（“SEC”）提交的報告，包括但不限於公司截至 2024 年 10 月 31 日的年度報告（表格 20-F）及其後續向 SEC 提交的文件。前瞻性聲明僅在聲明發布之日有效。公司不承擔更新前瞻性聲明以反映實際結果、後續事件或情況、假設變化或影響前瞻性信息的其他因素變化的義務，除非適用的證券法要求。如果公司更新一項或多項前瞻性聲明，不應推斷公司將就此或其他前瞻性聲明進行額外更新。提供的參考和鏈接僅為方便，網站上包含的信息不被納入本新聞稿。Clearmind 對第三方網站的內容不承擔責任。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EVTVNeU0zTXpRd09ERXhJelV3TURBNE5qa3pOQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxODU5MyM3MzQwODExIzUwMDA4NjkzNA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2ZjODFhNTktZWY0MC00MzQ4LWIzNzQtMGI3M2RkYzU1YTY5LTUwMDA4NjkzNC0yMDI1LTEyLTMxLWVu/tiny/Clearmind-Medicine-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/M2ZjODFhNTktZWY0MC00MzQ4LWIzNzQtMGI3M2RkYzU1YTY5LTUwMDA4NjkzNC0yMDI1LTEyLTMxLWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

Clearmind Medicine 重新符合納斯達克最低出價要求 | CMND 股票新聞